4801 Amber Valley Parkway
Fargo, ND 58104
Ph: 701.239.4750
Fax: 701.239.4955

Cetero’s Fargo facility incorporates more than 25 years of clinical pharmacology research experience into one facility. Designed to conduct studies in healthy and select special population participants, Fargo has completed more than 5,000 studies.

Purpose-built and designed to take clinical pharmacology projects from study design through final report, the Fargo facility has a strong reputation for conducting drug interaction, TQT and bioequivalence studies.

With 120 dedicated ICU-style hospital beds, TQT trials can be accommodated in fewer cohorts and are run by experienced physicians, nurses and clinical staff. To date, our largest enrollment of a single cohort included 70 subjects, while the largest TQT study completed has included 280 participants.  In addition to the vast TQT experience, Fargo offers a wide range of Phase I study capabilities.

Fargo’s participant database includes more than 120,000 men and women available for Phase I-III studies, including, but not limited to: healthy men and women, smokers, postmenopausal women, participants with allergies, asthma, depression and dermatological conditions.

Our comprehensive Phase I capabilities, including protocol writing, data management, PK/PD and biostatistics, bioanalytical, project management, monitoring and medical writing, allow us to provide you with a full-service program of clinical drug development.

Contact us today to discuss your next project at 877.7CETERO or fargo@cetero.com.

Fargo Study Capabilities First-in-Human Single and multiple ascending dose in healthy participants or patients Proof-of-Concept Interaction Drug-drug, drug-food, and alcohol interaction Bioavailability Absolute bioavailability, bioequivalence Pharmacokinetic (PK) Dose proportionality and age/gender Pharmacodynamic (PD) Objective or subjective measures performed in-house or with patient diaries Thorough QT In addition, Fargo has preclinical and clinical dermatology study experience in: In vitro percutaneous absorption Human safety testing Claims substantiation Topical pharmaceutical testing Topical PK studies